Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma

  • Mansour, Sahar F (Pathology Department, Faculty of Medicine, Suez Canal University) ;
  • Atwa, Maha M (Pathology Department, Faculty of Medicine, Suez Canal University)
  • Published : 2015.12.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Biomarkers in breast neoplasms provide invaluable information regarding prognosis and help determining the optimal treatment. We investigated the possible correlation between cancer stem cell (CSC) markers (CD133, and ALDH1) in invasive ductal breast carcinomas with some clinicopathological parameters. Aim: To assess the correlation between expression of cancer stem cell (CSC) markers (CD133, and ALDH1) and clinicopathological parameters of invasive ductal breast carcinomas. Materials and Methods: Immunohistochemical analysis of CD133 and ALDH1 was performed on a series of 120 modified radical mastectomy (MRM) specimens diagnosed as invasive ductal breast carcinoma. Results: Expression of both CD133 and ALDH1 was significantly changed and related to tumor size, tumor stage (TNM), and lymph node metastasis. A negative correlation between CD133 and ALDH1 was found. Conclusions: Detecting the expression of CD133 and ALDH1 in invasive ductal breast carcinomas may be of help in more accurately predicting the aggressive properties and determining the optimal treatment.

Keywords

References

  1. Alison MR, Guppy NJ, Lim SM, et al (2010). Finding cancer stem cells, are aldehyde dehydrogenases fit for purpose?. J Pathol, 222, 335-44. https://doi.org/10.1002/path.2772
  2. Bertolini G, Roz L, Perego P, et al (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U.S.A, 106, 16281-6. https://doi.org/10.1073/pnas.0905653106
  3. Bexell D, Gunnarsson S, Siesjo P, et al (2009). CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. International J Cancer, 125, 15-22. https://doi.org/10.1002/ijc.24306
  4. Bozzi F, Conca E, Manenti G, et al (2011). High CD133 expression levels in gastrointestinal stromal tumors. Cytometry B Clin Cytom, 80, 238-47.
  5. Charafe-Jauffret E, Ginestier C, Iovino F, et al (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res, 16, 45-55. https://doi.org/10.1158/1078-0432.CCR-09-1630
  6. Clark MF, and Fuller M (2006). Stem cells and cancer, Two faces of eve. Cell, 124, 1111-5. https://doi.org/10.1016/j.cell.2006.03.011
  7. Clevers H (2011). The cancer stem cell, Premises, promises and challenges. Nat Med, 17, 313-9. https://doi.org/10.1038/nm.2304
  8. Deng S, Yang X, Lassus H, et al (2010). Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One, 5, 10277. https://doi.org/10.1371/journal.pone.0010277
  9. Di Bonito M, Collina F, Cantile M, et al (2012). Aberrant expression of cancer stem cells marker prominin-1 in low-grade tubulobular breast carcinoma, a correlative study between qRT-PCR, Flow-Cytometric and Immunohistochemistry Analysis. J Breast Cancer, 15, 15-23. https://doi.org/10.4048/jbc.2012.15.1.15
  10. Douville J, Beaulieu R & Balicki D (2009). ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev, 18, 17-25. https://doi.org/10.1089/scd.2008.0055
  11. Ferlay J, Soerjomataram I, Ervik M, et al (2013). Cancer Incidence and Mortality Worldwide (2013). IARC Cancer Base No. 11 Lyon, France, International Agency for Research on Cancer. GLOBOCAN v1.0
  12. Gaur P, Sceusi EL, Samuel S, et al (2011). Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology, 141, 1728-37. https://doi.org/10.1053/j.gastro.2011.07.037
  13. Huang EH, Hynes MJ, Zhang T, et al (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res, 69, 3382-9. https://doi.org/10.1158/0008-5472.CAN-08-4418
  14. Ibrahim A, Khaled H, Mikhail N, et al (2014). Cancer incidence in Egypt, results of the national population-based cancer registry program. J Cancer Epidemiology.
  15. Ieni A, Giuffre G, Adamo V, et al (2011). Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas. Anticancer Res, 31, 1315-20.
  16. Jiang F, Qiu Q, Khanna A, et al (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res, 7, 330-8. https://doi.org/10.1158/1541-7786.MCR-08-0393
  17. Keymoosi H, Gheytanchi E, Asgari M, et al (2014). ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev, 15, 2013-20. https://doi.org/10.7314/APJCP.2014.15.5.2013
  18. Lamy PJ, Martin PM, Romieu G, et al (2013). Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for earlystage breast cancer, a systematic review. J Natl Cancer Inst, 105, 149.
  19. Liao Y, Hu X, Huang X, et al (2010). Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biological & Pharmaceutical Bulletin, 33, 738-742. https://doi.org/10.1248/bpb.33.738
  20. Madjd Z, Ramezani B, Molanae S, et al (2012). High Expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev, 13, 2973-8. https://doi.org/10.7314/APJCP.2012.13.6.2973
  21. Meacham C, and Morrison S (2013), Tumor heterogeneity and cancer cell plasticity. Nature, 501, 328-37. https://doi.org/10.1038/nature12624
  22. Meyer M, Fleming J, Ali M, et al (2009). Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 11, R82. https://doi.org/10.1186/bcr2449
  23. Mills J, and Shivdasani R (2011). Gastric epithelial stem cells. Gastroenterology, 140, 412-24. https://doi.org/10.1053/j.gastro.2010.12.001
  24. Morimoto K, Kim S, Tanei T, et al (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci, 100, 1062-8. https://doi.org/10.1111/j.1349-7006.2009.01151.x
  25. Navin N, Kendall J, Troge J, et al (2011). Tumor evolution inferred by single-cell sequencing. Nature, 472, 90-4. https://doi.org/10.1038/nature09807
  26. Ohi Y, Umekita Y, Yoshioka T, et al (2011). Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology, 59, 776-80 https://doi.org/10.1111/j.1365-2559.2011.03884.x
  27. Park SY, Lee HE, Li H, et al (2010). Heterogeneity for stem cellrelated markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res, 16, 876-87. https://doi.org/10.1158/1078-0432.CCR-09-1532
  28. Rao Q, Yao T, Zhang B, et al (2012). Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pac J Cancer Prev, 13, 1325-31. https://doi.org/10.7314/APJCP.2012.13.4.1325
  29. Rasha M Abd El Atti, Riham M Abu-Zeid (2012). CD133 and FGF7. Egyptian Journal of Pathology, 32, 142-9. https://doi.org/10.1097/01.XEJ.0000417559.72626.ac
  30. Resetkova E, Reis-Filho J, Jain R, et al (2010). Prognostic impact of ALDH1 in breast cancer, a story of stem cells and tumor microenvironment. Breast Cancer Res Treat, 123, 97-108. https://doi.org/10.1007/s10549-009-0619-3
  31. Reya T, Morrison S, Clarke M, et al (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105-11. https://doi.org/10.1038/35102167
  32. Sakakibara M, Fujimori T, Miyoshi T, et al (2012). Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. Cancer, 118, 3899-910. https://doi.org/10.1002/cncr.26725
  33. Saricanbaz I, Karahacioglu E, Ekinci O, et al (2014). Prognostic significance of expression of CD133 and Ki-67 in gastric cancer. Asian Pac J Cancer Prev, 15, 8215-9. https://doi.org/10.7314/APJCP.2014.15.19.8215
  34. Satpute P, Hazarey V, Ahmed R et al (2013). Cancer stem cells in head and neck squamous cell carcinoma, a review. Asian Pac J Cancer Prev, 14, 5579-87. https://doi.org/10.7314/APJCP.2013.14.10.5579
  35. Schneider M, Huber J, Hadaschik B, et al (2012). Characterization of colon cancer cells, a functional approach characterizing CD133 as a potential stem cell marker," BMC Cancer, 12, 96. https://doi.org/10.1186/1471-2407-12-96
  36. Shi C, Tian R, Wang M, et al (2010). CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther, 10, 1182-90. https://doi.org/10.4161/cbt.10.11.13664
  37. Shimada Y, Ishii G, Nagai K et al (2009). Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci, 100, 2054-9. https://doi.org/10.1111/j.1349-7006.2009.01295.x
  38. Tessari A, Palmieri D, Di Cosimo S (2013). Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med, 7, 1-19.
  39. Timothy E, Wang D, Harki D (2013). Cell surface markers of cancer stem cells, diagnostic macromolecules and targets for drug delivery. Drug Delivery and Translational Research, 3, 121-42. https://doi.org/10.1007/s13346-012-0075-1
  40. Tirino V, Camerlingo R, Franco R, et al (2009). The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg, 36, 446-53. https://doi.org/10.1016/j.ejcts.2009.03.063
  41. Turner N, Pestrin M, Galardi F, et al (2014). Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel), 6, 684-707. https://doi.org/10.3390/cancers6020684
  42. Visvader J, and Lindeman G (2008). Cancer stem cells in solid tumours, Accumulating evidence and unresolved questions. Nat Rev Cancer, 8, 755-68. https://doi.org/10.1038/nrc2499
  43. Wang K, Liu L, Zhang T, et al (2011). Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine, 6, 3207-18.
  44. Wright M, Calcagno A, Salcido C, et al (2008). Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res, 10, 10.
  45. Wu Y, and Wu P (2009). CD133 as a marker for cancer stem cells, progresses and concerns. Stem Cells Dev, 18, 1127-34. https://doi.org/10.1089/scd.2008.0338
  46. Yan X, Ma L, Yi D, et al (2011). A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A, 108, 1591-6. https://doi.org/10.1073/pnas.1018696108
  47. Zhao P, Lu Y, Jiang X, et al (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci, 102, 1107-11. https://doi.org/10.1111/j.1349-7006.2011.01894.x
  48. Zobalova R, Prokopova K, Stantic M, et al (2011). The Potential role of CD133 in immune surveillance and apoptosis, a mitochondrial connection? Antioxidants & Redox Signaling, 15, 2989-3002. https://doi.org/10.1089/ars.2010.3785

Cited by

  1. Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer" and the "Commentary by Antonio Ieni and Giovanni Tuccari" vol.19, pp.3, 2016, https://doi.org/10.4048/jbc.2016.19.3.336
  2. miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer vol.37, pp.2, 2017, https://doi.org/10.3892/or.2017.5360
  3. miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer vol.37, pp.5, 2017, https://doi.org/10.3892/or.2017.5532
  4. Epithelial–mesenchymal transition and gastric cancer stem cell vol.39, pp.5, 2017, https://doi.org/10.1177/1010428317698373
  5. miR-196a-5p modulates gastric cancer stem cell characteristics by targeting Smad4 vol.50, pp.6, 2017, https://doi.org/10.3892/ijo.2017.3965
  6. Relationship between microvessel density and cancer stem cells in tumor angiogenesis: a meta-analysis vol.10, pp.8, 2016, https://doi.org/10.2217/bmm-2016-0026
  7. ALCAM+ stromal cells: role in giant cell tumor of bone progression vol.9, pp.3, 2018, https://doi.org/10.1038/s41419-018-0361-z
  8. Cytokeratin 19 (KRT19) has a Role in the Reprogramming of Cancer Stem Cell-Like Cells to Less Aggressive and More Drug-Sensitive Cells vol.19, pp.5, 2018, https://doi.org/10.3390/ijms19051423